Comparative Pharmacology
Head-to-head clinical analysis: DEFERASIROX versus DEFERIPRONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEFERASIROX versus DEFERIPRONE.
DEFERASIROX vs DEFERIPRONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Deferasirox is an oral iron chelator that binds trivalent iron (Fe3+) with high affinity, forming a stable complex that is excreted primarily in the feces. It reduces iron burden in transfusion-dependent patients.
Deferiprone is an iron chelator that binds to ferric iron (Fe3+) to form a stable complex, promoting iron excretion in urine. It reduces iron overload in tissues and prevents iron-induced free radical damage.
Initial: 20 mg/kg orally once daily. Maintenance: 20-40 mg/kg orally once daily (maximum 40 mg/kg/day).
75 mg/kg/day orally in three divided doses (maximum 3 g/day).
None Documented
None Documented
Terminal elimination half-life is 8–16 hours in patients with transfusional iron overload; higher iron burden prolongs half-life due to enterohepatic recirculation.
Clinical Note
moderateDeferasirox + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Deferasirox."
Clinical Note
moderateDeferasirox + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Deferasirox."
Clinical Note
moderateTiaprofenic acid + Deferasirox
"The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Deferasirox."
Clinical Note
moderateCarprofen + Deferasirox
2-3 hours (terminal elimination half-life). Due to its short half-life, multiple daily doses are required to maintain therapeutic chelation; levels decline rapidly after dose cessation.
Primarily fecal (84%) as unchanged drug via biliary excretion; renal excretion accounts for approximately 8% as unchanged drug and metabolites.
Primarily renal excretion as iron complex (ferrioxamine) and unchanged drug; 70-90% of a dose is recovered in urine within 24 hours, predominantly as the iron chelate. Less than 10% is eliminated in feces via biliary excretion.
Category C
Category C
Iron Chelator
Iron Chelator
"The risk or severity of adverse effects can be increased when Carprofen is combined with Deferasirox."